Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 3 1Phase 2 1

Status

Withdrawn 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Multiple Myeloma 85Lymphoma, Follicular 18Recurrence 11Lymphoma, Large B-Cell, Diffuse 11Neoplasms, Plasma Cell 8Lymphoma 7Lymphoma, B-Cell, Marginal Zone 6Lymphoma, Non-Hodgkin 5Neoplasms 4Lymphoma, Mantle-Cell 4Hematologic Diseases 4Smoldering Multiple Myeloma 3Leukemia, Lymphocytic, Chronic, B-Cell 3Disease Progression 3Paraproteinemias 2Myelodysplastic Syndromes 2Disease 2Anemia 2Sezary Syndrome 1Prostatic Neoplasms 1Polycythemia Vera 1Plasmacytoma 1Neoplasm Metastasis 1Mycosis Fungoides 1Melanoma 1Lymphoproliferative Disorders 1Lymphoma, T-Cell, Cutaneous 1Limb-girdle muscular dystrophy, type 2C 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Acute 1

Interventions

Zoledronic Acid 1Vorinostat 1Lenalidomide 1Denosumab 1Bortezomib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Blood Protein Disorders × Lenalidomide × Clear all
NCT02155634 2018-04-10

Continuous Lenalidomide Therapy Versus Observation Following Induction Without Lenalidomide, Pomalidomide or Thalidomide in Myeloma

Celgene

Phase 3 Withdrawn
Plasma cell

Blood Protein Disorders, Hematologic Diseases, Multiple Myeloma, Neoplasms, Paraproteinemias

Data powered by HemOnc (CC BY 4.0) Colophon âš¡